Dexin China Holdings Company Limited
Dexin China Holdings Company Limited Fundamental Analysis
Dexin China Holdings Company Limited (2019.HK) shows weak financial fundamentals with a PE ratio of -0.10, profit margin of -8.93%, and ROE of -40.11%. The company generates $24.6B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -48.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 2019.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2019.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent2019.HK trades at attractive valuation levels.
Growth Score
Weak2019.HK faces weak or negative growth trends.
Financial Health Score
Moderate2019.HK shows balanced financial health with some risks.
Profitability Score
Weak2019.HK struggles to sustain strong margins.
Key Financial Metrics
Is 2019.HK Expensive or Cheap?
P/E Ratio
2019.HK trades at -0.10 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 2019.HK's PEG of -0.00 indicates potential undervaluation.
Price to Book
The market values Dexin China Holdings Company Limited at 0.05 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 14.38 times EBITDA. This signals the market has high growth expectations.
How Well Does 2019.HK Make Money?
Net Profit Margin
For every $100 in sales, Dexin China Holdings Company Limited keeps $-8.93 as profit after all expenses.
Operating Margin
Core operations generate -3.08 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-40.11 in profit for every $100 of shareholder equity.
ROA
Dexin China Holdings Company Limited generates $-2.86 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Dexin China Holdings Company Limited produces operating cash flow of $4.88B, showing steady but balanced cash generation.
Free Cash Flow
Dexin China Holdings Company Limited generates strong free cash flow of $4.85B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.63 in free cash annually.
FCF Yield
2019.HK converts 21.83% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-0.10
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.05
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.009
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
3.77
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.08
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.40
vs 25 benchmark
ROA
Return on assets percentage
-0.03
vs 25 benchmark
ROCE
Return on capital employed
-0.05
vs 25 benchmark
How 2019.HK Stacks Against Its Sector Peers
| Metric | 2019.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -0.10 | 22.38 | Better (Cheaper) |
| ROE | -40.11% | 721.00% | Weak |
| Net Margin | -8.93% | -37440.00% (disorted) | Weak |
| Debt/Equity | 3.77 | -20.85 (disorted) | Distorted |
| Current Ratio | 1.08 | 1953.62 | Neutral |
| ROA | -2.86% | -1450.00% (disorted) | Weak |
2019.HK outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Dexin China Holdings Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Income, Inflation Hedge, REIT
EPS CAGR
N/A
Industry Style: Income, Inflation Hedge, REIT
FCF CAGR
N/A
Industry Style: Income, Inflation Hedge, REIT